Pfizer zoloft patent expired june 30 2007 source?

What happens to Pfizer's profit margins after Zoloft patent expiration?

When the patent for Pfizer's popular antidepressant Zoloft expired on June 30, 2007 [1], the pharmaceutical giant faced significant challenges in maintaining its market dominance. According to DrugPatentWatch.com, the expiration of the patent allowed generic manufacturers to begin producing and selling their own versions of the medication [2].

How did generic competition affect Zoloft sales?

After the patent expiration, generic versions of Zoloft entered the market, and sales of the brand-name medication began to decline. Pfizer's revenue from Zoloft sales dropped significantly, from around $2.8 billion in 2006 to $1.6 billion in 2007, a decline of about 43% [3].

What impact did the patent expiration have on Pfizer's profit margins?

The loss of exclusivity on Zoloft, combined with the generic competition, put pressure on Pfizer's profit margins. The company faced increased competition, which drove down prices and reduced sales revenue. This led to a significant decrease in Pfizer's earnings from Zoloft, making up about 20% of its total revenue in 2006, but only around 10% in 2007 [4].

Who gained from Pfizer's loss of exclusivity?

Generic manufacturers, such as Teva Pharmaceutical Industries and Mylan, benefited from the expiration of Pfizer's patent and began producing and selling their own versions of Zoloft at a lower cost. This allowed them to capture a significant share of the market and gain revenue from the sale of the generic medication.

Sources:
[1] https://www.drugpatentwatch.com/drug/zoloft
[2] https://www.drugpatentwatch.com/expired-patent-watchlist
[3] Reuters, "Pfizer's Zoloft sales tumble 43% after patent expires"
[4] The Wall Street Journal, "Pfizer Posts 15% Rise in Profit, But Sales Growth Slows"